UNFO Med

Company Overview

Snapshot

Founded in July 2010 by Dr. Izak Daizade, UNFO Med operates with 1–10 employees. The company has developed a patented Universal Neonatal Foot Orthotics (UNFO) device, receiving FDA approval in the United States and CE mark approval in Europe.

Business overview

UNFO Med develops medical devices within the Health Tech & Life Sciences sector, specifically focusing on assistive devices and medical treatment. The company's core product is the Universal Neonatal Foot Orthotics (UNFO) device, a corrective foot brace designed for the treatment of metatarsus adductus (MTA) in newborns. This technology aims to provide an effective, safe, and stress-free alternative to traditional methods like casting, serving patients, parents, and healthcare providers in markets including the United States, Europe, and South Korea.

Strategic signal

In May 2017, UNFO Med was featured in a news article highlighting its innovative approach to helping toddlers with foot conditions. This coverage underscores the company's commitment to addressing critical needs in pediatric orthopedics and signals its potential for broader market adoption and impact in the healthcare industry.

Company Intelligence Q&A

What is UNFO Med's primary product?

UNFO Med's primary product is the Universal Neonatal Foot Orthotics (UNFO) device, a child-friendly corrective foot brace developed for the treatment of metatarsus adductus (MTA) in newborns.

When was UNFO Med founded and by whom?

UNFO Med was founded in July 2010 by Dr. Izak Daizade.

In which markets has UNFO Med received regulatory approvals?

UNFO Med has received FDA approval in the United States and CE mark approval in Europe for its products.

What is the employee count for UNFO Med?

UNFO Med operates with 1–10 employees.

Which countries are key markets for UNFO Med?

UNFO Med has clients and operates in markets including Israel, Italy, Africa, Ukraine, South Korea, United States, Europe, Brazil, South Africa, India, Canada, and Australia.